Trastuzumab: tested in a combination

382 studies: another drug in the study is under test too. Page 3 of 4. Open to participants first (81), then studies with results posted, then the rest; newest registration first within each.

• PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast CancerActive, not recruitingNCT06172127Phase 2Report a problem
• A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)Active, not recruitingNCT06100874Phase 2Report a problem
• Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid CancersCompletedNCT06083662Phase 2Report a problem
• Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-BlockadeActive, not recruitingNCT06068985Phase 2Report a problem
• Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.CompletedNCT05997524Phase 2Report a problem
• Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABCCompletedNCT05969184Phase 2Report a problem
• STOP-HER2: Stopping Trastuzumab in HER2+ MBCActive, not recruitingNCT05721248Phase 2Report a problem
• Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaActive, not recruitingNCT05715931Phase 2Report a problem
• Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast CancerTerminatedNCT05583110Phase 2Report a problem
• Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast CancerStatus unknownNCT05577442Phase 2Report a problem
• Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast CancerActive, not recruitingNCT05574881Phase 1/2Report a problem
• Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric AdenocarcinomaCompletedNCT05504720Phase 2Report a problem
• Tucatinib+Trastuzumab+Eribulin in HER2+ MBCActive, not recruitingNCT05458674Phase 2Report a problem
• Precise Therapy for Refractory HER2 Positive Advanced Breast CancerStatus unknownNCT05429684Phase 3Report a problem
• Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038Status unknownNCT05429294Phase 2Report a problem
• Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T StudyWithdrawnNCT05356897Phase 2Report a problem
• PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast CancerStatus unknownNCT05346107Phase 2Report a problem
• Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaActive, not recruitingNCT05256225Phase 3Report a problem
• Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast CancerStatus unknownNCT05255523Phase 2Report a problem
• SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1Report a problem
• Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal CancerStatus unknownNCT05193292Phase 2Report a problem
• Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard TherapyTerminatedNCT05180006Phase 2Report a problem
• H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World StudyStatus unknownNCT05167643Not applicableReport a problem
• Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast CancerStatus unknownNCT05076695Phase 2Report a problem
• Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and PyrotinibStatus unknownNCT05020964Phase 2Report a problem
• Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast CancerStatus unknownNCT04997798Phase 2Report a problem
• Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults with Recurrent or Residual Posterior Fossa EpendymomaCompletedNCT04958486Early Phase 1Report a problem
• Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.WithdrawnNCT04896320Phase 1/2Report a problem
• Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast CancerActive, not recruitingNCT04733118Phase 2Report a problem
• Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line TherapyCompletedNCT04722133Phase 2Report a problem
• De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 BlockadeTerminatedNCT04675827Phase 2Report a problem
• Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal DiseaseActive, not recruitingNCT04588545Phase 1/2Report a problem
• A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast CancerActive, not recruitingNCT04569747Phase 2Report a problem
• CRAFT: The NCT-PMO-1602 Phase II TrialCompletedNCT04551521Phase 2Report a problem
• Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)Active, not recruitingNCT04383275Phase 2Report a problem
• A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGCCompletedNCT04309578Phase 2Report a problem
• Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)CompletedNCT04296162Phase 2Report a problem
• Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung CancerActive, not recruitingNCT04285671Phase 1/2Report a problem
• Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric AdenocarcinomaCompletedNCT04281576Not applicableReport a problem
• Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid TumorStatus unknownNCT04215159Phase 2Report a problem
• Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast CancerStatus unknownNCT04152057Phase 1/2Report a problem
• Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast CancerActive, not recruitingNCT04126525Phase 2Report a problem
• Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast CancerStatus unknownNCT04088110Phase 2Report a problem
• Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast CancerStatus unknownNCT03994107Phase 1/2Report a problem
• Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast CancerStatus unknownNCT03933319Phase 2Report a problem
• Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast CancerTerminatedNCT03931551Phase 2Report a problem
• Tucatinib + Abemaciclib + Herceptin for HER2+ MBCWithdrawnNCT03846583Phase 1Report a problem
• Her2-positive Lung Cancer Treated With Dedicated DrugCompletedNCT03845270Phase 2Report a problem
• Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.Status unknownNCT03843749Not applicableReport a problem
• Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerActive, not recruitingNCT03803553Phase 3Report a problem
• Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric CancerWithdrawnNCT03766607Phase 2Report a problem
• DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BCActive, not recruitingNCT03716180Phase 1Report a problem
• Combination of Nanoxel and Herzuma in Salivary Duct CarcinomaStatus unknownNCT03614364Phase 2Report a problem
• Herzuma-capecitabine/Cisplatin for Gastric CancerStatus unknownNCT03588533Phase 2Report a problem
• Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 StatusStatus unknownNCT03457896Phase 2Report a problem
• Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 SignalingStatus unknownNCT03412643Phase 2Report a problem
• Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast CancerActive, not recruitingNCT03368729Phase 1/2Report a problem
• 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)TerminatedNCT03367676Phase 2Report a problem
• Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic BreastActive, not recruitingNCT03304080Phase 1/2Report a problem
• Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal CancerStatus unknownNCT03225937Phase 2Report a problem
• Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive SystemStatus unknownNCT03185988Phase 2Report a problem
• Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.Active, not recruitingNCT03161353Phase 2Report a problem
• Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2CompletedNCT02907021Phase 1Report a problem
• Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric CancerStatus unknownNCT02805829Phase 1/2Report a problem
• Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent EpendymomaCompletedNCT02774421Phase 1Report a problem
• Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal CancerCompletedNCT02725424Phase 2Report a problem
• NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast CancerStatus unknownNCT02689921Phase 2Report a problem
• Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialActive, not recruitingNCT02678182Phase 2Report a problem
• Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2Report a problem
• PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC TrialActive, not recruitingNCT02624973Phase 2Report a problem
• Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast CancerTerminatedNCT02598427Phase 1Report a problem
• Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast CancerTerminatedNCT02598310Phase 2Report a problem
• FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ CancerCompletedNCT02581462Phase 2/3Report a problem
• Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast CancerTerminatedNCT02571530Phase 1Report a problem
• A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast CancerCompletedNCT02488564Phase 2Report a problem
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2Report a problem
• Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal TherapyCompletedNCT02411344Phase 2Report a problem
• Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast CancerCompletedNCT02402712Phase 3Report a problem
• Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver MetastasisStatus unknownNCT02380131Phase 4Report a problem
• Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- TumorsCompletedNCT02307227Phase 2Report a problem
• Paclitaxel-trastuzumab in EGFR-mutated NSCLC PatientsStatus unknownNCT02226757Phase 2Report a problem
• Neoadjuvant Trastuzumab and Letrozole for Postmenopausal WomenStatus unknownNCT02214004Phase 2Report a problem
• Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT02205047Phase 2Report a problem
• Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive PatientsCompletedNCT02152943Phase 1Report a problem
• Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal CarcinomaCompletedNCT02120911Phase 1/2Report a problem
• Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast CancerWithdrawnNCT02102438Not applicableReport a problem
• Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast CancerStatus unknownNCT02059876Phase 2Report a problem
• NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric CancerStatus unknownNCT02030561Phase 1/2Report a problem
• Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric CancerCompletedNCT02004769Phase 2Report a problem
• Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast CancerWithdrawnNCT01985893Phase 2Report a problem
• PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast CancerCompletedNCT01973660Phase 2Report a problem
• Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + LapatinibCompletedNCT01875666Early Phase 1Report a problem
• Trastuzumab & Pertuzumab Followed by T-DM1 in MBCCompletedNCT01835236Phase 2Report a problem
• A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT ProtocolCompletedNCT01817452Phase 2Report a problem
• A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction CancerCompletedNCT01748773Phase 2Report a problem
• A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerCompletedNCT01736410Phase 2Report a problem
• Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast CancerCompletedNCT01669239Phase 2Report a problem
• "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"Status unknownNCT01641406Phase 2Report a problem
• Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)PositiveCompletedNCT01503983Phase 2Report a problem
• Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or StomachCompletedNCT01472029Phase 2Report a problem

← Trastuzumab